 |
|
Effect of Pentoxifylline in Severe Sepsis
Results of a Randomized, Double-blind, Placebo-Controlled Study
Karl-Hermann Staubach, MD;
Jörg Schröder, MD;
Frank Stüber, MD;
Katrin Gehrke, MD;
Emanuel Traumann, MD;
Peter Zabel, MD
Arch Surg. 1998;133:94-100.
Objective To evaluate the effect of pentoxifylline on organ dysfunction, survival, and mediator response in patients with severe sepsis.
Design Randomized, double-blind, placebo-controlled study.
Setting Surgical intensive care units at 2 university hospitals.
Patients Fifty-one surgical patients with severe sepsis were randomized to receive pentoxifylline continuously (27 patients) or saline infusion as placebo (24 patients).
Interventions Patients received pentoxifylline (1 mg/kg of body weight per hour; maximum, 1800 mg/d) during 28 days or until they were discharged from the intensive care unit or died.
Measurements and Main Results Vital signs and organ function were determined at diagnosis; daily from day 1 to 7; on days 10, 14, 17, 21, and 24; and 28 days after diagnosis of sepsis. There were no differences in characteristics of patients at diagnosis in the Acute Physiology and Chronic Health Evaluation II (APACHE II) score (mean±SEM, 17±4 points for the pentoxifylline group and 18±5 points for the placebo group), the multiple organ dysfunction score (mean±SEM, 11.0±0.8 vs 11.8±1.0 points), tumor necrosis factor  and interleukin 6 bioactivity, serum endotoxin levels, or organ dysfunction. At study entrance, 23 of 27 patients in the pentoxifylline group and 21 of 24 patients in the placebo group experienced septic shock. No adverse effects of pentoxifylline treatment were observed. The 28-day mortality rate was 30% (8/27) in pentoxifylline-treated patients and 33% (8/24) in the placebo group. Hospital mortality was 41% (11/27) in the pentoxifylline group and 54% (13/24) in the placebo group. The multiple organ dysfunction score decreased in patients receiving pentoxifylline 4 days after diagnosis of sepsis compared with placebo-treated patients; a significant difference was reached on day 14 (P<.05; Student t test, Bonferoni correction). The PaO2/FIO2 (fraction of inspired oxygen) ratio was significantly improved in pentoxifylline-treated patients on days 14 and 17 (P<.05), and the pressure-adjusted heart rate was significantly improved on day 6 (P<.05) compared with the placebo group. Serum endotoxin levels, tumor necrosis factor and interleukin 6 bioactivity were not different between the groups during the study.
Conclusions Continuous intravenous administration of pentoxifylline beneficially influenced cardiopulmonary dysfunction in patients with sepsis without adverse effects. Larger trials are needed to evaluate the efficacy in improving organ function in relation to the outcome for patients with severe sepsis.
From the Department of Surgery, Medical School, University of Lübeck, Lübeck (Drs Staubach and Traumann); the Departments of General and Thoracic Surgery (Drs Schröder and Gehrke) and Anesthesiology (Dr Stüber), University of Kiel, Kiel; and the Department of Internal Medicine, Research Institute of Borstel, Borstel (Dr Zabel), Germany. Dr Stüber is now with the Department of Anesthesiology, University of Bonn, Bonn, Germany.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Understanding the Inflammatory Cytokine Response in Pneumonia and Sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study
Kellum et al.
Arch Intern Med 2007;167:1655-1663.
ABSTRACT
| FULL TEXT
Cell Response to Surgery
Ni Choileain and Redmond
Arch Surg 2006;141:1132-1140.
ABSTRACT
| FULL TEXT
The intraoperative effect of pentoxifylline on the inflammatory process and leukocytes in cardiac surgery patients undergoing cardiopulmonary bypass
Cagli et al.
Perfusion 2005;20:45-51.
ABSTRACT
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury
Rocco et al.
Eur Respir J 2003;22:20-27.
ABSTRACT
| FULL TEXT
Pentoxifylline Rescue Preserves Lung Function in Isolated Canine Lungs Injured With Phorbol Myristate Acetate
Creamer et al.
Chest 2001;119:1893-1900.
ABSTRACT
| FULL TEXT
Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients
Boldt et al.
Ann. Thorac. Surg. 2001;71:1524-1529.
ABSTRACT
| FULL TEXT
Pentoxifylline prevents the transition from the hyperdynamic to hypodynamic response during sepsis
Yang et al.
Am. J. Physiol. Heart Circ. Physiol. 1999;277:H1036-H1044.
ABSTRACT
| FULL TEXT
Increasing Doses of Pentoxifylline as a Continuous Infusion in Canine Septic Shock
Quezado et al.
J. Pharmacol. Exp. Ther. 1999;288:107-113.
ABSTRACT
| FULL TEXT
Pentoxifylline in Sepsis
Maier
Arch Surg 1998;133:466-466.
FULL TEXT
|
